|Bid||31.80 x 300|
|Ask||33.80 x 300|
|Day's Range||31.55 - 33.75|
|52 Week Range||2.70 - 37.62|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Examining Mirati Therapeutics Inc’s (NASDAQ:MRTX) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, whichRead More...
The San Diego-based company said it had a loss of 65 cents per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for ...
H.C. Wainwright has initiated bullish coverage of four healthcare stocks headed into the end of 2017. Analyst Edward White explained his positive take on the four stocks in a research note on Thursday. ...
Citigroup in a note released Monday, delved into the roadmap for Mirati Therapeutics, Inc. (NASDAQ: MRTX ). The firm feels the response for its targeted agent sitravatinib in CBL-mutated non-small cell ...
Mirati Therapeutics (MRTX) needs Investors to pay close attention to the stock based on moves in the options market lately.
Mirati Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Mirati Therapeutics Inc (NASDAQ:MRTX), a pharmaceuticals, biotechnology and life sciences company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM in theRead More...
Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, ...
The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.
The San Diego-based company said it had a loss of 74 cents per share. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
The San Diego-based company said it had a loss of 73 cents per share. The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...